Clinical Trial Update: Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes CART-138, a CAR-T cell therapy, being studied in Phase 1/2 for chemotherapy-refractory multiple myeloma. The sponsor is Chi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CART-138

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN